Pharmaceutical Japan-headquartered ophthalmology specialist Santen Pharmaceutical has received approval for the transfer of the Marketing Authorization of the rho kinase inhibitors (ROCK inhibitors) Rhokiinsa (netarsudil 200mcg/ml eye drops, solution) and Roclanda (latanoprost 50mcg/ml and netarsudil 200mcg/ml eye drops, solution) in the European Economic Area (EEA) from the European Medicines Agency (EMA) and in the UK from the Medicines and Healthcare products Regulatory Agency (MHRA). 2 March 2022